Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC51 vs JE-VAX for Japanese Encephalitis
NCT00604708Phase 3Completed
- Sponsor
- Valneva
- Start
- Sep 2005
- Primary completion
- Sep 2006
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, single-blind trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE) (2 arms), sponsored by Valneva. Primary endpoints: Seroconversion Rate at Day 56 and Geometric Mean Titer at Day 56. Started Sep 2005; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT00604708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604708.